Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular therapy: donor lymphocyte infusion.

K S Peggs1, S Mackinnon

  • 1Department of Hematology, University College Hospital, London, UK.

Current Opinion in Hematology
|October 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMT.

British journal of haematology·2021
Same author

ENT trainees' experience of redeployment during the coronavirus disease 2019 pandemic: a qualitative study.

The Journal of laryngology and otology·2021
Same author

Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening.

Bone marrow transplantation·2020
Same author

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplants.

Bone marrow transplantation·2017
Same author

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Bone marrow transplantation·2017
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Stem cell transplantation

Area of Science:

  • Hematology and Oncology
  • Immunology

Background:

  • Chemoradiotherapy dose escalation with stem cell transplantation may not fully eradicate malignancy.
  • An immune-mediated graft-versus-malignancy (GVM) effect is crucial for disease control in many conditions.

Purpose of the Study:

  • To review the evidence and challenges associated with the graft-versus-malignancy effect in stem cell transplantation.
  • To discuss strategies for optimizing GVM responses while minimizing graft-versus-host disease (GVHD).

Main Methods:

  • Review of existing literature on GVM effects and donor lymphocyte infusions (DLIs).
  • Analysis of response rates in various hematologic malignancies treated with stem cell transplantation and DLIs.
  • Discussion of unresolved issues and future research directions.

Related Experiment Videos

Main Results:

  • Donor lymphocyte infusions show efficacy in anti-tumor responses, especially for chronic myeloid leukemia.
  • Response rates are variable and generally lower for myeloma, acute myeloid leukemia, myelodysplasia, and acute lymphoblastic leukemia.
  • Limited data exists for indolent lymphoid malignancies, and GVHD remains a significant obstacle.

Conclusions:

  • The GVM effect is a vital component of successful stem cell transplantation, complementing direct anti-cancer therapies.
  • Further research is needed to identify effector cells and target antigens, and to develop strategies for separating GVM from GVHD.
  • Optimizing GVM requires careful consideration of nonmyeloablative protocols and potential adjuvant therapies.